Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Fosun Pharma Invests $15 Million in US Early Stage Medical Fund

publication date: May 10, 2017
Shanghai Fosun Pharma will invest $15 million in Partners Innovation Fund II, a fund that will invest in medical research products originating from Partners Healthcare System of Boston. Partners Healthcare includes three major Boston-area teaching hospitals that are associated with Harvard University: Massachusetts General Hospital, Brigham and Women’s Hospital and McLean Hospital. Fosun said it was interested in PIFII as an investment, but also for potential acquisitions and China rights to promising products. More details....

Stock Symbols: (SHA: 600196; HK: 2196)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming event
August 25-27, 2020
China Standard Time
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China